SEC Comment Letter for Matinas BioPharma Holdings, Inc. (MTNB) (CIK 0001582554) (MTNB) — Sep 24, 2019
Matinas BioPharma Holdings, Inc. (MTNB) (CIK 0001582554)
Date: Sept. 24, 2019 · CIK: 0001582554 · Accession: 0000000000-19-013895
AI Filing Summary & Sentiment
File numbers found in text: 001-38022
Letter
September 24, 2019 Jerome D. Jabbour Chief Executive Officer Matinas BioPharma Holdings, Inc. 1545 Route 206 South Suite 302 Bedminster, New Jersey 07921 Re:Matinas BioPharma Holdings, Inc. Preliminary Proxy Statement on Schedule 14A Filed September 13, 2019 File No. 001-38022 Dear Mr. Jabbour: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Steven M. Skolnick, Esq.
Show Raw Text
September 24, 2019
Jerome D. Jabbour
Chief Executive Officer
Matinas BioPharma Holdings, Inc.
1545 Route 206 South
Suite 302
Bedminster, New Jersey 07921
Re:Matinas BioPharma Holdings, Inc.
Preliminary Proxy Statement on Schedule 14A
Filed September 13, 2019
File No. 001-38022
Dear Mr. Jabbour:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Steven M. Skolnick, Esq.